NR1H4 and type 2 diabetes mellitus: In type 2 diabetic mice, the FXR antagonist Mebhydrolin improved glucose homeostasis by suppressing hepatic gluconeogenesis via FXR/miR-22-3p/PI3K/AKT/FoxO1 pathway.